Testing

John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.

William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, recently shared with the Advisory Board his insight into the potential that digital pathology and out-of-lab testing can bring into the laboratory space.

This page lists updates posted to Mayo Clinic Labs during the month of October.

Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.

Dr. Leslie Donato recently joined “Laborastories: The Podcast,” hosted by the Association for Diagnostics & Laboratory Medicine (ADLM) president Dr. Anthony Killeen, to discuss the publication of the new ADLM lipid and lipoprotein testing document. The document highlights best practices and new guidance regarding lipid and lipoprotein testing to ensure the best care for patients with heart disease, while educating clinical laboratorians on the most recent evidence-based improvements in the testing space.

Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many kinds of cancer.

This page lists updates posted to Mayo Clinic Labs during the month of September.

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

This page lists updates posted to Mayo Clinic Labs during the month of August.

Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.

This page includes updates posted to Mayo Clinic Labs during the month of July.